WASHINGTON — House Oversight Chairman Elijah Cummings (Md.) isn’t the only newly empowered Democrat with his eyes on drug makers.

Rep. Diana DeGette of Colorado, the newly minted chair of the Energy and Commerce Committee’s oversight arm, is also planning to haul industry CEOs before her own panel, she said Wednesday at a briefing with reporters.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I might subscribe if wasn’t for the tease of a gov’t oversight committee article, which last I looked you didn’t pay for on a free perhaps no longer open internet.
    What you produce warrents renumeration but not this….Soooooo! WOT

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy